Income StatementBalance SheetCash FlowSegments
Amgen logo

Amgen Cash Flow Statement

Operating, investing, and financing cash movements

Amgen generated $10.8B in operating cash flow over the trailing twelve months. After $2.2B in capital expenditures, free cash flow was $8.6B. Free cash flow decreased 0.2% year-over-year. Based on the Q1 2026 filing.

Net Cash From Operating (TTM)$10.8BNet Cash From Investing (TTM)-$2.2BNet Cash From Financing (TTM)-$5.3BCapital Expenditures (TTM)$2.2BDepreciation And Amortization Cf (TTM)$4.9BNet Change In Cash (TTM)-$1.3B
Latest FilingQ1 2026
Report Date2026-04-30
Market Cap$183.12B
P/E Ratio23.48
ROE101.32%

Operating

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Other non-cash income (expense)$38.0M$50.0M$23.0M$28.0M-$250.0M$67.0M
Stemcentrx Impairment Charge$30.0M$800.0M—$400.0M—$0.0
Change in Accrued Sales Incentives$658.0M$486.0M$627.0M$1.2B—-$839.0M
Change in Long-term Tax Liabilities—$70.0M$92.0M$74.0M$75.0M$71.0M
Change in accounts payable—$497.0M$589.0M——$571.0M
Change in accounts receivable-$473.0M$1.3B$515.0M$0.0$1.1B-$413.0M
Change in accrued liabilities$728.0M-$874.0M$824.0M-$200.0M$749.0M-$959.0M
Change in income taxes payable/receivable—$104.0M-$2.4B—-$365.0M$71.0M
Change in inventories-$323.0M-$288.0M-$239.0M-$240.0M-$119.0M-$18.0M
Change in other assets$14.0M$201.0M$206.0M$283.0M$577.0M-$8.0M
Change in other liabilities—-$78.0M$0.0-$10.0M-$76.0M-$75.0M
Other working capital changes$38.0M$50.0M$23.0M$28.0M-$250.0M$67.0M
Deferred income taxes-$334.0M-$250.0M-$422.0M-$30.0M-$19.0M-$176.0M
Depreciation and amortization$1.4B$1.4B$1.3B$1.3B$1.1B$1.1B
Net gains (losses) on investments-$876.0M$1.3B—$2.0B—-$143.0M
Impairment charges$30.0M$800.0M—$400.0M—$0.0
Other Non-Cash Income (Expense)$38.0M$50.0M$23.0M$28.0M-$250.0M$67.0M
Other Non-cash Income (Expense)$38.0M$50.0M$23.0M$28.0M-$250.0M$67.0M
Other Non-cash Income (Expense)$38.0M$50.0M$23.0M$28.0M-$250.0M$67.0M
Net cash from operating activities$4.8B$1.4B$2.3B$4.7B$1.6B$2.2B
Net income$627.0M$1.7B$1.4B$3.2B$1.3B$1.8B
Other non-cash income (expense)$38.0M$50.0M$23.0M$28.0M-$250.0M$67.0M
Increase (Decrease) in Other Operating Assets$14.0M$201.0M$206.0M$283.0M$577.0M-$8.0M
Other Noncash Income (Expense)$38.0M$50.0M$23.0M$28.0M-$250.0M$67.0M
Other Non-cash Income and Expense$38.0M$50.0M$23.0M$28.0M-$250.0M$67.0M
Other Non-Cash Adjustments$38.0M$50.0M$23.0M$28.0M-$250.0M$67.0M
Other Non-Cash Income and Expense$38.0M$50.0M$23.0M$28.0M-$250.0M$67.0M
Impairment of Goodwill and Other Intangibles$30.0M$800.0M—$400.0M—$0.0
Stock-based compensation$134.0M$85.0M$157.0M$127.0M$125.0M$75.0M

Financing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Debt Extinguishment Costs—$301.0M$301.0M$81.0M$0.0$233.0M
Payments of Debt Extinguishment Costs—$301.0M$301.0M$81.0M$0.0$233.0M
Proceeds from issuance of debt$0.0$0.0———$4.0B
Repayments of debt$0.0$2.5B$1.0B$1.5B$0.0$833.0M
Dividends paid$1.2B$1.3B$1.3B$1.3B$1.3B$1.4B
Other, net-$2.0M-$27.0M-$92.0M——-$104.0M
Payment for Debt Extinguishment Costs—$301.0M$301.0M$81.0M$0.0$233.0M
Payment of Deferred Purchase Consideration-$2.0M-$27.0M-$92.0M——-$104.0M
Noncontrolling interest transactions and other-$2.0M-$27.0M-$92.0M——-$104.0M
Net cash from financing activities-$1.4B-$4.1B-$2.7B-$2.9B-$1.2B$1.4B
Other financing activities-$2.0M-$27.0M-$92.0M——-$104.0M
Noncontrolling Interests Activity and Other-$2.0M-$27.0M-$92.0M——-$104.0M
Payment for Debt Extinguishment Costs—$301.0M$301.0M$81.0M$0.0$233.0M
Payment for Debt Extinguishment or Prepayment Cost—$301.0M$301.0M$81.0M$0.0$233.0M
Payment for debt extinguishment or prepayment costs—$301.0M$301.0M$81.0M$0.0$233.0M
Premiums Paid to Extinguish Debt—$301.0M$301.0M$81.0M$0.0$233.0M

Investing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Capital expenditures$371.0M$411.0M$369.0M$436.0M$642.0M$712.0M
Payment for (Proceeds from) Other Investing Activity—$36.0M$20.0M——$4.0M
Net cash from investing activities-$402.0M-$447.0M-$389.0M-$414.0M-$693.0M-$716.0M
Other investing activities—$36.0M$20.0M——$4.0M

Free Cash Flow

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Free cash flow$4.4B$980.0M$1.9B$4.2B$961.0M$1.5B

Other

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Net increase (decrease) in cash$3.0B-$3.2B-$782.0M—-$316.0M$2.9B
Unrealized Gain (Loss) on Investments-$876.0M$1.3B—$2.0B—-$143.0M